American Century Companies
OCUL icon

American Century Companies’s Ocular Therapeutix OCUL Stock Holding History

American Century Companies’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74,491
Closed -$648K – 2935
2024
Q3 		$648K Buy
+74,491
New +$614K ﹤0.01% 2383

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

American Century Companies's OCUL Position: Q4 2024 in Review

American Century Companies sold out of Ocular Therapeutix (OCUL) in Q4 2024, closing a stake of 74,491 shares — an estimated $648K sold.

American Century Companies first reported a position in OCUL in Q3 2024 and held it in 1 quarter. The position peaked at $648K in Q3 2024. 179 funds tracked by Wall St. Rank hold OCUL as of Q4 2024.

  • American Century Companies reported no remaining Ocular Therapeutix position as of Q4 2024 after selling out during the quarter.
  • American Century Companies sold 74,491 Ocular Therapeutix shares in Q4 2024, an estimated $648K.
  • American Century Companies first reported a position in Ocular Therapeutix in Q3 2024 and held it in 1 quarter.
  • American Century Companies's Ocular Therapeutix position peaked at $648K in Q3 2024.
  • 179 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2024.

Based on American Century Companies's 13F filing for Q4 2024, filed 11 Feb 2025.